Zobrazeno 1 - 10 of 66 pro vyhledávání: '"N. Delev"'
5
Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients
Autor: Benoit Guerette, N. Delev, Maria Paris, Jacob A. Aelion, Paul Bird, Alvin F. Wells, Alan Kivitz, Christopher J Edwards, L. Teng
Publikováno v: Rheumatology. 61:1035-1043
Objectives Apremilast monotherapy was evaluated up to 5 years in PALACE 4 (fourth PsA Long-term Assessment of Clinical Efficacy study) DMARD-naïve patients with PsA. Methods Patients with active PsA were randomized (1:1:1) to placebo, apremilast 30
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b460d96bf078d84046186c3a8599934
https://doi.org/10.1093/rheumatology/keab449
Zobrazit plný text záznamu
6
Long‐Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials
Autor: Juan J. Gomez-Reino, Stephen Hall, Philip J. Mease, Georg Schett, N. Delev, Dafna D. Gladman, L. Teng, Eric Lespessailles, Jürgen Wollenhaupt, Maria Paris, Arthur Kavanaugh
Publikováno v: ACR Open Rheumatology, Vol 2, Iss 8, Pp 459-470 (2020)
ACR Open Rheumatology
ACR Open Rheumatology, 2020, ⟨10.1002/acr2.11156⟩
OBJECTIVE Psoriatic arthritis (PsA) requires long-term treatment, yet safety concerns and monitoring requirements make maintenance a challenge. This analysis of pooled Psoriatic Arthritis Long-term Assessment of Clinical Efficacy (PALACE) 1, 2, and 3
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af41e432a10f189798b6e0b38a4874d5
https://doaj.org/article/fa93086f13fa47d6bce83b4a9731f08f
Zobrazit plný text záznamu
7
LB0004 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYK2 INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Autor: E. Morand, M. Pike, J. T. Merrill, R. Van Vollenhoven, V. P. Werth, C. Hobar, N. Delev, V. Shah, B. Sharkey, T. Wegman, I. Catlett, S. Banerjee, S. Singhal
Publikováno v: Annals of the Rheumatic Diseases. 81:209-209
BackgroundTyrosine kinase 2 (TYK2) mediates signaling of Type I interferons, IL-23, and IL-12, key cytokines involved in lupus pathogenesis. Deucravacitinib (DEUC) is an oral, selective, allosteric TYK2 inhibitor with a unique mechanism of action, di
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::86576d747eb3ed8502b3432387fc8db9
https://doi.org/10.1136/annrheumdis-2022-eular.5020a
Zobrazit plný text záznamu
8
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
9
OP0132 EFFECT OF IBERDOMIDE ON CUTANEOUS MANIFESTATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF A 24-WEEK, PLACEBO-CONTROLLED, PHASE 2 STUDY
Autor: Thomas Dörner, Victoria P. Werth, R. Van Vollenhoven, N. Delev, M. Stern, S. Korish, Peter E. Lipsky, S. Tang, M. Weiswasser, P. Schafer, Richard Furie, Joan T. Merrill, Z. Liu
Publikováno v: Annals of the Rheumatic Diseases. 80:76-77
Background:Iberdomide is a high-affinity cereblon ligand that promotes proteasomal degradation of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factors involved in innate and adaptive immune cell development and homeostasis, and linked to the gene
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6122a1792ac4be06a3ed94ef63a3f060
https://doi.org/10.1136/annrheumdis-2021-eular.2181
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje